Author Interviews, Brigham & Women's - Harvard, Infections, JAMA, Multiple Sclerosis, Neurological Disorders / 19.03.2024
MS: Harvard Chan Study Further Identified Serologic Response to Epstein-Barr Virus
MedicalResearch.com Interview with:
[caption id="attachment_61454" align="alignleft" width="125"]
Dr. Cortese[/caption]
Marianna Cortese, MD, PhD
Senior Research ScientistDepartment of Nutrition
Harvard T.H. Chan School of Public HealthBoston, MA 02115
MedicalResearch.com: What is the background for this study?
Response: In a study published in Science in 2022, we reported compelling evidence that infection with the Epstein-Barr virus is the leading cause of Multiple Sclerosis. This is a follow-up study to investigate more in depth whether the antibody response to EBV is distinct in individuals with MS compared to individuals without MS and whether there is a part of EBV that the immune response is particularly targeting. For this purpose we assessed the immune response to all protein parts (peptides) of EBV and their association with MS.
Previous studies could only look at parts of EBV and this is the first study looking at all EBV peptides. Antibodies to EBV (especially to a protein called EBNA1) are known to be overall higher in individuals with MS, so we also tested whether immune response overall or the immune response to specific EBV protein parts was more important. If the immune response to a specific EBV protein part (peptide) would be standing out or distinguishing individuals with MS, we hypothesized, it could point to a specific mechanism of how EBV may cause MS, i.e. it could point for example towards “molecular mimicry”, which is when antibodies targeting a pathogen start targeting a body-own structure (for example in the brain) which resembles the protein parts of the pathogen.
Dr. Cortese[/caption]
Marianna Cortese, MD, PhD
Senior Research ScientistDepartment of Nutrition
Harvard T.H. Chan School of Public HealthBoston, MA 02115
MedicalResearch.com: What is the background for this study?
Response: In a study published in Science in 2022, we reported compelling evidence that infection with the Epstein-Barr virus is the leading cause of Multiple Sclerosis. This is a follow-up study to investigate more in depth whether the antibody response to EBV is distinct in individuals with MS compared to individuals without MS and whether there is a part of EBV that the immune response is particularly targeting. For this purpose we assessed the immune response to all protein parts (peptides) of EBV and their association with MS.
Previous studies could only look at parts of EBV and this is the first study looking at all EBV peptides. Antibodies to EBV (especially to a protein called EBNA1) are known to be overall higher in individuals with MS, so we also tested whether immune response overall or the immune response to specific EBV protein parts was more important. If the immune response to a specific EBV protein part (peptide) would be standing out or distinguishing individuals with MS, we hypothesized, it could point to a specific mechanism of how EBV may cause MS, i.e. it could point for example towards “molecular mimicry”, which is when antibodies targeting a pathogen start targeting a body-own structure (for example in the brain) which resembles the protein parts of the pathogen.
Dr. Fangqun Yu[/caption]
Dr. Fangqun Yu PhD
Senior Research Faculty
Atmospheric Sciences Research Center University
Albany, State University of New York
Dr. Arshad Nair[/caption]
Dr. Arshad Arjunan Nair PhD
Postdoctoral Associate
Atmospheric Sciences Research Center
University at Albany, State University of New York
Skilled
In recent years, the field of psychiatric care has undergone a revolutionary transformation. This is because of groundbreaking research that has redefined our understanding of mental health and treatment methodologies.
From innovative therapies to advanced diagnostic tools, transformative research has played a pivotal role in reshaping the landscape of psychiatric care.
In this article, we will explore the key contributions that researchers have made in this field. We will also talk about how their work is influencing the way mental health is approached and treated.
According to the AACR Cancer Progress Report, cancer survivors have significantly improved from 50 years ago. It constituted only 1.4 percent of the US population earlier, but they have increased considerably. The number of cancer survivors is estimated to grow to
The importance of external support systems becomes even more crucial as the number of children with disabilities and other developmental disorders continues to surge. This trend is apparent in academic settings, where there is a rising number of students with disabilities. According to the Pew Research Center, nearly
Dr. Magruder[/caption]
Matthew Magruder, MD PGY3
Orthopaedic Residency Program
Department of Orthopaedic Surgery and Rehabilitation
Maimonides Medical Center
MedicalResearch.com: What is the background for this study?
Response: The prevalence of obesity and diabetes mellitus has reached epidemic proportions. Approximately 37.3 million people in the United States, accounting for 11.3% of the total population, have diabetes, and 100.1 million, or 41.9%, of all US citizens are obese. Furthermore, these numbers are only projected to increase in the coming decades. This is an issue for orthopaedic surgeons because diabetes and obesity have consistently been demonstrated to be risk factors for complications following total joint replacements, especially total hip replacements. Therefore, we are in desperate need of new and more effective tools in mitigating the risk of poor outcomes in our joint replacement patients.
Semaglutide, and other GLP-1 agonists, are potentially a new tool that can be used to help decrease the risks following joint replacement surgery. Initially a medication to treat diabetes, semaglutide has recently been approved by the FDA to treat obesity as well, as randomized controlled trials have consistently demonstrated significant weight loss with minimal side effects. The purpose of our study was to see what effect the use of semaglutide had on total hip arthroplasty patient outcomes.
Dr. Akefe[/caption]
Isaac O Akefe DVM, PhD
Clem Jones Centre for Ageing Dementia Research
Queensland Brain Institute
The University of Queensland St Lucia
Academy for Medical Education, Medical School
Brisbane QLD Australia
MedicalResearch.com: What is the background for this study?
Response: The brain is the body’s fattiest organ, with fatty compounds called lipids making up 60% of its weight. Fatty acids are the building blocks of a class of lipids called phospholipids.
In our study, we first showed that levels of saturated fatty acids increase in the brain during neuronal communication and long-term memory formation, but we didn’t know what was causing these changes.
It is your lifestyle that determines your blood pressure levels. Your nutritional intake and the level of activity have a significant part as well.